A review of omalizumab for the management of severe asthma

References

• National Asthma Education ProgramGuidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. Expert Panel ReportJ Allergy Clin Immunol1991883 Pt 24255341890276
   PubMed Web of Science ®Google Scholar
• ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• National Asthma Education Prevention and ProgramExpert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007J Allergy Clin Immunol20071205 SupplS94S13817983880
   PubMed Web of Science ®Google Scholar
• ReddelHKTaylorDRBatemanEDAn official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practiceAm J Respir Crit Care Med20091801599919535666
   PubMed Web of Science ®Google Scholar
• Global Asthma NetworkGlobal Asthma Report 2014Auckland, New ZealandGlobal Asthma Network Available from: http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdfAccessed January 10, 2016
   Google Scholar
• Global Initiative for AsthmaGlobal Strategy for Asthma Management and PreventionGINA Reports2015 Available from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/Accessed January 10, 2016
   Google Scholar
• American Thoracic SocietyProceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questionsAm J Respir Crit Care Med200016262341235111112161
   PubMedGoogle Scholar
• Al EfraijKFitzGeraldJMCurrent and emerging treatments for severe asthmaJ Thorac Dis2015711E522E52526716048
   PubMed Web of Science ®Google Scholar
• KellyHWRationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelinesJ Allergy Clin Immunol20071205989994 quiz 995–99617983867
   PubMed Web of Science ®Google Scholar
• KerstjensHADisseBSchroder-BaboWTiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trialJ Allergy Clin Immunol2011128230831421636120
   PubMed Web of Science ®Google Scholar
• AbadogluOBerkSTiotropium may improve asthma symptoms and lung function in asthmatic patients with irreversible airway obstruction: the real-life dataClin Respir J201610442142725335652
   PubMed Web of Science ®Google Scholar
• KellerMKampDSevere asthma: the evolution of patient-directed managementClin Pulm Med20142111825580071
   PubMedGoogle Scholar
• WilhelmCPChippsBEBronchial thermoplasty: a review of the evidenceAnn Allergy Asthma Immunol20161162929826654482
   PubMed Web of Science ®Google Scholar
• ZhouJPFengYWangQZhouLNWanHYLiQYLong-term efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma: a systemic review and meta-analysisJ Asthma20165319410026383773
   PubMed Web of Science ®Google Scholar
• BostantzoglouCDelimpouraVSamitasKZervasEKanniessFGagaMClinical asthma phenotypes in the real world: opportunities and challengesBreathe201511318619326632421
   PubMed Web of Science ®Google Scholar
• QuirceSBoboleaIDominguez-OrtegaJBarrancoPFuture biologic therapies in asthmaArch Bronconeumol201450835536124685200
   PubMed Web of Science ®Google Scholar
• MenzellaFLusuardiMGaleoneCZucchiLTailored therapy for severe asthmaMultidiscip Respir Med2015101125671117
   PubMedGoogle Scholar
• GalliSJTsaiMIgE and mast cells in allergic diseaseNat Med201218569370422561833
   PubMed Web of Science ®Google Scholar
• HamelmannEThe rationale for treating allergic asthma with anti-IgEEur Respir J2007161046166
   Google Scholar
• SchulmanESDevelopment of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disordersAm J Respir Crit Care Med20011648 Pt 2S6S1111704611
   PubMed Web of Science ®Google Scholar
• MacGlashanDJrLichtensteinLMMcKenzie-WhiteJUpregulation of FcεRI on human basophils by IgE antibody is mediated by interaction of IgE with FcεRIJ Allergy Clin Immunol19991042 Pt 149249810452777
   PubMed Web of Science ®Google Scholar
• BeckLAMarcotteGVMacGlashanDTogiasASainiSOmalizumab-induced reductions in mast cell Fcε RI expression and functionJ Allergy Clin Immunol2004114352753015356552
   PubMed Web of Science ®Google Scholar
• MacGlashanDWJrBochnerBSAdelmanDCDown-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibodyJ Immunol19971583143814459013989
   PubMed Web of Science ®Google Scholar
• SamitasKDelimpouraVZervasEGagaMAnti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectivesEur Respir Rev20152413859460126621973
   PubMed Web of Science ®Google Scholar
• CorrenJCasaleTBLanierBBuhlRHolgateSJimenezPSafety and tolerability of omalizumabClin Exp Allergy200939678879719302249
   PubMed Web of Science ®Google Scholar
• CorrenJFroehlichJSchoenhoffMPhase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthmaJ Allergy and Clin Immunol1996971245
   Web of Science ®Google Scholar
• FroehlichJInitial human study with a humanized recombinant anti-IgE monoclonal antibody: safety, tolerance and pharmacokinetic (PK)/dynamic profileClin Pharmacol Ther1995572162
   Web of Science ®Google Scholar
• HumbertMBeasleyRAyresJBenefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy200560330931615679715
   PubMed Web of Science ®Google Scholar
• WalkerSMonteilMPhelanKLassersonTJWaltersEHAnti-IgE for chronic asthma in adults and childrenCochrane Database Syst Rev20062CD00355916625585
   PubMed Web of Science ®Google Scholar
• MolimardMde BlayFDidierALe GrosVEffectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in FranceRespir Med20081021717617920257
   PubMed Web of Science ®Google Scholar
• BrusselleGMichilsALouisR“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST studyRespir Med2009103111633164219619998
   PubMed Web of Science ®Google Scholar
• BarnesNMenzies-GowAMansurAHEffectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world studyJ Asthma201350552953623574000
   PubMed Web of Science ®Google Scholar
• CazzolaMCamiciottoliGBonaviaMItalian real-life experience of omalizumabRespir Med2010104101410141620483574
   PubMed Web of Science ®Google Scholar
• BraunstahlGJChenCWMaykutRGeorgiouPPeacheyGBruceJThe eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthmaRespir Med201310781141115123721684
   PubMed Web of Science ®Google Scholar
• LanierBBridgesTKulusMTaylorAFBerhaneIVidaurreCFOmalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthmaJ Allergy Clin Immunol200912461210121619910033
   PubMed Web of Science ®Google Scholar
• MilgromHBergerWNayakATreatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)Pediatrics20011082E3611483846
   PubMed Web of Science ®Google Scholar
• NormansellRWalkerSMilanSJWaltersEHNairPOmalizumab for asthma in adults and childrenCochrane Database Syst Rev20141CD00355924414989
   PubMed Web of Science ®Google Scholar
• DeschildreAMarguetCSalleronJAdd-on omalizumab in children with severe allergic asthma: a 1-year real life surveyEur Respir J20134251224123323520319
   PubMed Web of Science ®Google Scholar
• OdajimaHEbisawaMNagakuraTOmalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapyAllergol Int201564436437026433533
   PubMed Web of Science ®Google Scholar
• MaykutRJKianifardFGebaGPResponse of older patients with IgE-mediated asthma to omalizumab: a pooled analysisJ Asthma200845317318118415822
   PubMed Web of Science ®Google Scholar
• KornSSchumannCKropfCEffectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthmaAnn Allergy Asthma Immunol2010105431331920934632
   PubMed Web of Science ®Google Scholar
• VermaPRandhawaIKlaustermeyerWBClinical efficacy of omalizumab in an elderly veteran population with severe asthmaAllergy Asthma Proc201132534635022195686
   PubMed Web of Science ®Google Scholar
• HolgateSTHow to evaluate a patient’s response to anti-IgEEur Respir Rev2007161047884
   Google Scholar
• BousquetJRabeKHumbertMPredicting and evaluating response to omalizumab in patients with severe allergic asthmaRespir Med200710171483149217339107
   PubMed Web of Science ®Google Scholar
• BousquetJSiergiejkoZSwiebockaEPersistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthmaAllergy201166567167821255035
   PubMed Web of Science ®Google Scholar
• LinHBoeselKMGriffithDTOmalizumab rapidly decreases nasal allergic response and FcεRI on basophilsJ Allergy Clin Immunol2004113229730214767445
   PubMed Web of Science ®Google Scholar
• PrussinCGriffithDTBoeselKMLinHFosterBCasaleTBOmalizumab treatment downregulates dendritic cell FcεRI expressionJ Allergy Clin Immunol200311261147115414657874
   PubMed Web of Science ®Google Scholar
• CorrenJShapiroGReimannJAllergen skin tests and free IgE levels during reduction and cessation of omalizumab therapyJ Allergy Clin Immunol2008121250651118269927
   PubMed Web of Science ®Google Scholar
• SlavinRGFerioliCTannenbaumSJMartinCBloggMLowePJAsthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrationsJ Allergy Clin Immunol20091231107.e3113.e319130931
   PubMed Web of Science ®Google Scholar
• NoppAJohanssonSGAdedoyinJAnkerstJPalmqvistMOmanHAfter 6 years with Xolair; a 3-year withdrawal follow-upAllergy2010651566019796193
   PubMed Web of Science ®Google Scholar
• NoppAJohanssonSGAnkerstJPalmqvistMOmanHCD-sens and clinical changes during withdrawal of Xolair after 6 years of treatmentAllergy200762101175118117845588
   PubMed Web of Science ®Google Scholar
• LowePJRenardDOmalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgEBr J Clin Pharmacol201172230632021392073
   PubMed Web of Science ®Google Scholar
• MolimardMMalaLBourdeixILe GrosVObservational study in severe asthmatic patients after discontinuation of omalizumab for good asthma controlRespir Med2014108457157624565601
   PubMed Web of Science ®Google Scholar
• BusseWTrazskomaBOmachiTEvaluating omalizumab persistency of response after long-term therapy (XPORT)Eur Respir J201444Suppl 583485
   Google Scholar
• Ministry of Health and WelfareCause of Death Data from Department of StatisticsMinistry of Health and Welfare Available from: http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2473Accessed January 10, 2016
   Google Scholar
• WuWFWanKSWangSJYangWLiuWLPrevalence, severity, and time trends of allergic conditions in 6-to-7-year-old schoolchildren in TaipeiJ Invest Allergol Clin Immunol2011217556562
   PubMed Web of Science ®Google Scholar
• KuoHPEffectiveness, safety and treatment persistence of add-on omalizumab in Taiwanese patients with uncontrolled severe persistent asthma (the EXACT study)Presented at: 4th IPCRG Scientific MeetingMay 28–30, 2015Singapore
   Google Scholar
• ChenHCHuangCDChangEKuoHPEfficacy of omalizumab (XolairR) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort studyBMC Pulm Med2016161326747278
   PubMedGoogle Scholar
• HugginsKGBrostoffJLocal production of specific IgE antibodies in allergic-rhinitis patients with negative skin testsLancet19752792614815049744
   PubMed Web of Science ®Google Scholar
• DomingoCOmalizumab for severe asthma: efficacy beyond the atopic patient?Drugs201474552153324691707
   PubMed Web of Science ®Google Scholar
• GarciaGMagnanAChironRA proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthmaChest2013144241141923579324
   PubMed Web of Science ®Google Scholar
• GevaertPCalusLVan ZeleTOmalizumab is effective in allergic and nonallergic patients with nasal polyps and asthmaJ Allergy Clin Immunol20131311110.e1116.e123021878
   PubMed Web of Science ®Google Scholar
• de LlanoLPVennera MdelCAlvarezFJEffects of omalizumab in non-atopic asthma: results from a Spanish multicenter registryJ Asthma201350329630123350994
   PubMed Web of Science ®Google Scholar
• OwenCEImmunoglobulin E: role in asthma and allergic disease: lessons from the clinicPharmacol Ther2007113112113317000005
   PubMed Web of Science ®Google Scholar
• ChervinskyPCasaleTTownleyROmalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisAnn Allergy Asthma Immunol200391216016712952110
   PubMed Web of Science ®Google Scholar
• VignolaAMHumbertMBousquetJEfficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy200459770971715180757
   PubMed Web of Science ®Google Scholar
• AdelrothERakSHaahtelaTRecombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitisJ Allergy Clin Immunol2000106225325910932067
   PubMed Web of Science ®Google Scholar
• NagakuraTOginoSOkuboKSatoNTakahashiMIshikawaTOmalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitisClin Exp Allergy200838232933718070163
   PubMed Web of Science ®Google Scholar
• OkuboKOginoSNagakuraTIshikawaTOmalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitisAllergol Int200655437938617130680
   PubMedGoogle Scholar
• PintoJMMehtaNDiTineoMWangJBaroodyFMNaclerioRMA randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitisRhinology201048331832421038023
   PubMed Web of Science ®Google Scholar
• BachertCGevaertPHoltappelsGJohanssonSGvan CauwenbergePTotal and specific IgE in nasal polyps is related to local eosinophilic inflammationJ Allergy Clin Immunol2001107460761411295647
   PubMed Web of Science ®Google Scholar
• VerbruggenKVan CauwenbergePBachertCAnti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps?Int Arch Allergy Immunol20091482879818799888
   PubMed Web of Science ®Google Scholar
• PennRMikulaSThe role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot studyAm J Rhinol200721442843217882911
   PubMedGoogle Scholar
• GarmhausenDHagemannTBieberTCharacterization of different courses of atopic dermatitis in adolescent and adult patientsAllergy201368449850623452057
   PubMed Web of Science ®Google Scholar
• HarskampCTArmstrongAWImmunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapiesSemin Cutan Med Surg201332313213924175400
   PubMed Web of Science ®Google Scholar
• MaqboolSHsiehFMcDonnellJVasasDLangDSafety and efficacy of omalizumab in atopic dermatitis: a preliminary reportJ Allergy Clin Immunol20051152S106
   Google Scholar
• VigoPGHussainIGirgisKRPfuetzeBLCritchlowMEFisherJEffect of anti-IgE therapy on atopic eczema symptoms in patients with asthmaJ Allergy Clin Immunol20051152S104
   Google Scholar
• HeilPMMaurerDKleinBHultschTStinglGOmalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo-controlled and double blind pilot studyJ Dtsch Dermatol Ges201081299099820678148
   PubMed Web of Science ®Google Scholar
• HotzeMBaurechtHRodriguezEIncreased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholinesAllergy201469113213524111531
   PubMed Web of Science ®Google Scholar
• IyengarSRHoyteEGLozaAImmunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trialInt Arch Allergy Immunol20131621899323816920
   PubMed Web of Science ®Google Scholar
• RomanoCSellittoADe FanisUOmalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experienceClin Drug Invest2015353159168
   PubMed Web of Science ®Google Scholar
• ZinkAGensbaurAZirbsMTargeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumabActa Derm Venereol2016961727626059424
   PubMed Web of Science ®Google Scholar
• JacksonDJSykesAMalliaPJohnstonSLAsthma exacerbations: origin, effect, and preventionJ Allergy Clin Immunol201112861165117422133317
   PubMed Web of Science ®Google Scholar
• SearsMRJohnstonNWUnderstanding the September asthma epidemicJ Allergy Clin Immunol2007120352652917658590
   PubMed Web of Science ®Google Scholar
• OborneJMortimerKHubbardRBTattersfieldAEHarrisonTWQuadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trialAm J Respir Crit Care Med2009180759860219590019
   PubMed Web of Science ®Google Scholar
• StrunkRCBacharierLBPhillipsBRAzithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma studyJ Allergy Clin Immunol200812261138.e41144.e418951618
   PubMed Web of Science ®Google Scholar
• WeissKBGernJEJohnstonNWThe Back to School asthma study: the effect of montelukast on asthma burden when initiated prophylactically at the start of the school yearAnn Allergy Asthma Immunol2010105217418120674830
   PubMed Web of Science ®Google Scholar
• JohnstonSLPattemorePKSandersonGThe relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysisAm J Respir Crit Care Med19961543 Pt 16546608810601
   PubMed Web of Science ®Google Scholar
• TeachSJGillMATogiasAPreseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbationsJ Allergy Clin Immunol201513661476148526518090
   PubMed Web of Science ®Google Scholar